US › Healthcare

Haemonetics Corporation (HAE)

US · Healthcare · Medical Devices

$85.38-1.62%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$346.4M
Revenue YoY
+4.8%
Net profit
$-20.1M
Profit YoY
-134.7%
EPS
$1.29
EPS estimate
$1.27
Net margin
-5.8%

EPS came in at 1.29 against a street estimate of 1.27 — a beat of 1.6%.

Key statistics

Market cap
$3.94B
P/E
42.3
Forward P/E
16.4
P/B
4.88
Book value
$17.60
EPS (TTM)
$2.05
52-week high
$88.58
52-week low
$47.32
50-day MA
$74.52
200-day MA
$67.63
Beta
0.52

Analyst view

Analysts rate Haemonetics Corporation a buy (8 buy, 1 hold, 1 sell out of 10) with an average price target of $86.60.

Shareholding

Insiders
1.22%
Institutions
110.22%

Largest institutional holders

FundStake
BlackRock Inc12.37%
Vanguard Group Inc10.48%
Neuberger Berman Group LLC7.84%
AQR Capital Management LLC7.39%
Vanguard Portfolio Management, LLC5.63%
Vanguard Capital Management, LLC4.60%
State Street Corp3.90%
Arrowstreet Capital Limited Partnership3.04%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Haemonetics Corporation — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.